Search Results

uniQure N.V. announced that it has entered into an agreement for the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus technologies.

Genezen, a best-in-class gene therapy CDMO, announced an agreement to acquire uniQure’s commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.

Genezen announced licensing of the Cytegrity™ proprietary stable production system from biotechnology leader CSL.

Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia program.

Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization, announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners.

Genezen, a gene and cell therapy contract development and manufacturing organization, announced the appointment of Susan D’Costa, Ph.D. as Chief Technology Officer and Nicole O’Brien, Ph.D. as Chief Commercial Officer.

Genezen announced a poster presentation at the 26th Annual American Society for Gene and Cell Therapy Conference in Los Angeles in May – highlighting the results of its evaluation of novel technologies for lentiviral physical titer determination.